BidaskClub lowered shares of Myokardia (NASDAQ:MYOK) from a buy rating to a hold rating in a research report sent to investors on Friday.
MYOK has been the subject of several other reports. ValuEngine downgraded Myokardia from a hold rating to a sell rating in a research note on Friday, December 1st. Zacks Investment Research downgraded Myokardia from a hold rating to a sell rating in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. assumed coverage on Myokardia in a research note on Tuesday, December 12th. They set an overweight rating and a $54.00 target price for the company. Finally, Credit Suisse Group reiterated an outperform rating and set a $60.00 target price on shares of Myokardia in a research note on Thursday, January 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $63.00.
Myokardia (MYOK) opened at $53.05 on Friday. Myokardia has a one year low of $10.80 and a one year high of $62.83.
In related news, insider Jake Bauer sold 5,000 shares of Myokardia stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $42.89, for a total transaction of $214,450.00. Following the completion of the sale, the insider now directly owns 62,877 shares of the company’s stock, valued at approximately $2,696,794.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Kevin P. Starr sold 816,326 shares of Myokardia stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 848,326 shares of company stock valued at $35,859,872. 33.40% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors lifted its holdings in Myokardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 2,591 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in Myokardia during the 2nd quarter worth approximately $148,000. SG Americas Securities LLC acquired a new stake in Myokardia during the 4th quarter worth approximately $185,000. The Manufacturers Life Insurance Company lifted its holdings in Myokardia by 38.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 4,215 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Myokardia during the 3rd quarter worth approximately $202,000. 83.91% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3257065/bidaskclub-lowers-myokardia-myok-to-hold.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.